Clinical pharmacology of oral antidiabetic agents (second of two parts).

Clinical pharmacology of oral antidiabetic agents (first of two parts).

Clinical pharmacokinetics (second of two parts).

Gastrin (second of two parts).

Histamine (second of two parts).

Lung defense mechanisms (second of two parts).

Bronchodilator therapy (second of two parts).

Renal transplantation (second of two parts).

Polymyositis and dermatomyositis (second of two parts).

Clinical pharmacology of the neuromuscular blocking agents.

Vasodilator therapy of cardiac failure (second of two parts).

The pathogenesis of atherosclerosis (second of two parts).

The reliability of clinical methods, data and judgments (second of two parts).

Catecholamines and neurologic diseases (second of two parts).

Basic and clinical concepts related to vitamin D metabolism and action (second of two parts).

Oxygen-dependent microbial killing by phagocytes (second of two parts).

Drug therapy: antiplatelet therapy (second of two parts).

New oral thiazolidinedione antidiabetic agents act as insulin sensitizers.

Perfluorocarbon-based antidiabetic agents.

Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications.

Clinical pharmacology of dopamine-modulating agents in Tourette's syndrome.

Pharmacogenetics of oral antidiabetic drugs.

Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus.

Antidiabetic agents and vascular events.

Regulation of respiration: (second of three parts).

Suggest Documents

Clinical pharmacology of oral antidiabetic agents (first of two parts).

Clinical pharmacokinetics (second of two parts).

Gastrin (second of two parts).

Histamine (second of two parts).

Lung defense mechanisms (second of two parts).

Bronchodilator therapy (second of two parts).

Renal transplantation (second of two parts).

Polymyositis and dermatomyositis (second of two parts).

Clinical pharmacology of the neuromuscular blocking agents.

Vasodilator therapy of cardiac failure (second of two parts).

The pathogenesis of atherosclerosis (second of two parts).

The reliability of clinical methods, data and judgments (second of two parts).

Catecholamines and neurologic diseases (second of two parts).

Basic and clinical concepts related to vitamin D metabolism and action (second of two parts).

Oxygen-dependent microbial killing by phagocytes (second of two parts).

Drug therapy: antiplatelet therapy (second of two parts).

New oral thiazolidinedione antidiabetic agents act as insulin sensitizers.

Perfluorocarbon-based antidiabetic agents.

Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications.

Clinical pharmacology of dopamine-modulating agents in Tourette's syndrome.

Pharmacogenetics of oral antidiabetic drugs.

Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus.

Antidiabetic agents and vascular events.

Regulation of respiration: (second of three parts).

Clinical pharmacology of oral antidiabetic agents (second of two parts).

Recommend Documents

Follow Us